Movement Alert｜Kodiak Sciences Inc. Intraday Rise 5.2% in Regular Trading, Phase 3 eye-drug progress and large insider buying remain in focus

Market Focus10-16

On October 16, Kodiak Sciences Inc. rose 5.2% in Regular Trading, trading at $85.31 per share, with turnover of $46.3375 million.

The move aligns with continued market digestion of two previously disclosed positives: the company said its eye-drug candidates Zenkuda and tabirafusp-ted met primary endpoints in a Phase 3 wet AMD study, while director Felix Baker bought about $157 million of shares in late September at roughly $80.85 per share.

Public filings and market reports indicated this was Baker's largest single purchase to date, executed through Baker Bros. Advisors, lifting the related funds' stake in Kodiak Sciences Inc. to about 35%. The earlier Phase 3 update had already driven a sharp rally, and the company also said it plans to submit data from five positive Phase 3 studies to regulators in the fourth quarter, helping keep attention on the stock.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment